Lucid Diagnostics (NASDAQ:LUCD) Receives Overweight Rating from Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $2.00 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 29.45% from the company’s current price.

Several other research analysts have also commented on the company. Needham & Company LLC raised their price target on Lucid Diagnostics from $2.50 to $3.00 and gave the stock a “buy” rating in a research report on Monday. Ascendiant Capital Markets lowered their target price on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a report on Monday, December 9th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $3.75.

Lucid Diagnostics Price Performance

Shares of LUCD stock traded down $0.01 during trading hours on Wednesday, hitting $1.55. The company had a trading volume of 238,982 shares, compared to its average volume of 634,399. The stock has a market capitalization of $91.68 million, a PE ratio of -1.36 and a beta of 1.34. The company’s fifty day moving average is $1.23 and its 200 day moving average is $0.99. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.63.

Hedge Funds Weigh In On Lucid Diagnostics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sunbelt Securities Inc. acquired a new stake in Lucid Diagnostics in the fourth quarter valued at approximately $67,000. Citadel Advisors LLC acquired a new position in Lucid Diagnostics during the 4th quarter worth approximately $98,000. Lido Advisors LLC increased its position in shares of Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock valued at $115,000 after purchasing an additional 40,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Lucid Diagnostics by 30.9% in the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock valued at $229,000 after purchasing an additional 65,964 shares in the last quarter. Finally, LPL Financial LLC lifted its position in shares of Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after purchasing an additional 12,035 shares during the last quarter. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.